Toggle Main Menu Toggle Search

Open Access padlockePrints

The Newcastle University research output collection, currently available on ePrints, will shortly be moving to a new open repository platform, Figshare. To prepare for the data migration we have paused adding new content to ePrints, and will resume once the new repository is launched. During this time you will continue to have access to ePrints (but no new content will appear). We will share updates here when available.

Considerations for the cure assumption in a NICE Single Technology Appraisal of nivolumab with chemotherapy for neoadjuvant treatment of resectable non-small cell lung cancer: Evidence Assessment Group perspective

Lookup NU author(s): Giovany Orozco LealORCiD, Eugenie JohnsonORCiD, Dr Sedighe Hosseinijebeli, Tomos Robinson, Tara HomerORCiD, Claire EastaughORCiD, Dr Louise TannerORCiD, Dr Nick MeaderORCiD, Dr Ryan KennyORCiD, Sheila WallaceORCiD, Stephen RiceORCiD

Downloads

Licence

This work is licensed under a Creative Commons Attribution 4.0 International License (CC BY 4.0).

Publication metadata

Author(s): Orozco Leal G, Johnson EE, Hosseinijebeli S, Robinson T, Homer T, Eastaugh C, Richmond C, Tanner L, Meader N, Kenny R, Wallace SA, Rice S

Publication type: Article

Publication status: Published

Journal: PharmacoEconomics

Year: 2024

Volume: 42

Pages: 133-136

Print publication date: 01/02/2024

Online publication date: 20/11/2023

Acceptance date: 09/10/2023

Date deposited: 11/12/2023

ISSN (print): 1170-7690

ISSN (electronic): 1179-2027

Publisher: Springer

URL: https://doi.org/10.1007/s40273-023-01328-w

DOI: 10.1007/s40273-023-01328-w

ePrints DOI: 10.57711/k6kc-8x77

Altmetrics

Altmetrics provided by Altmetric

Funding

Funder referenceFunder name
NIHR
NIHR135664

Share